MedTrace Logo

Effectiveness of Cortisone Injection and Splinting for Trigger Finger

NCT03156829 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2021-03-01

No results posted yet for this study

Summary

Trigger finger has a prevalence rate of up to 3%. There are many approaches available to manage this condition. While corticosteroid injection is widely accepted as the most common first-line treatment, its superiority over splint treatment has not been established. This study aims to test the effectiveness of cortisone injections, splint and cortisone+splint to resolve symptoms.

Conditions

  • Trigger Finger

Interventions

OTHER

Splint

Custom made splint

DRUG

Betamethasone

Corticosteroid Injection Brand name of the drug: Celestone Soluspan Dosage: 6 mg/ml

COMBINATION_PRODUCT

Splint + Cortico-steroid injection

Splint + Cortico-steroid injection given in combination

Sponsors & Collaborators

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Ruby Grewal, MD · Schulich School of Medicine and Dentistry\Surgery

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-27
Primary Completion
2021-09-01
Completion
2022-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03156829 on ClinicalTrials.gov